Abstract:
PROBLEM TO BE SOLVED: To prepare pharmaceutical preparation having no danger of a cytolytic or other toxic side effect and capable of eliminating an technical defect of use of a high viscosity material, etc., and improving permeability through an epithelial cell by including a (meth)acrylic acid-maleic acid copolymer. SOLUTION: This pharmaceutical preparation is the one for improving permeability through an epithelial cell and includes a (meth)acrylic acid-maleic acid copolymer e.g. the one composed of (A) 10-90mol% (meth)acrylic acid or its salt or anhydride, (B) 90-10mol% maleic acid or its salt or anhydride and (C) 0-40mol% monomer without components A and B [e.g. vinylsulfonic acid, a (meth)acrylic ester of a 2-6C hydroxyalkyl or a (meth)acrylic acid ester of 1-40C alkyl] and having 5,000-500,000, especially 10,000-300,000 weight average molecular weight}. The preparation is administered in a shape of a tablet, a granule, a suppository, an ointment, a solution, etc., by an oral, hypoglottis, oral cavity, pulmonary artery or pernasal administration, or an administration through ocular-mucous membrance.
Abstract:
PROBLEM TO BE SOLVED: To provide a powder shape finely crushed binder useful on the production of tablets, and to provide a method for producing the same. SOLUTION: This powder shape finely crushed binder comprises a vinyl lactam polymer, having an average particle size of ≤35 μm and an apparent density of ≤0.2 g/ml. The method for producing the binder comprises spraying a vinyl lactam polymer aqueous solution having a solid content of 1 to 35 wt.% with a single liquid nozzle under a pressure of ≥8 MPa or with a double liquid nozzle under a pressure of ≥0.2 MPa, and then drying the sprayed product with a hot gas flow. COPYRIGHT: (C)2007,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To obtain a water-soluble or water-dispersible polymer having overcome conventionally unsolved weak points as a coating agent, a binder and/or film-forming excipient in pharmaceutical dosage form, especially for instantly deliverable tablet. SOLUTION: This water-soluble or water-dispersible copolymer is obtained by free-radical polymerization in the presence of a) 80 to 20 wt.% of hydroxy-C1 to C6 alkyl (meth)acrylate and optionally one or more compounds expressed by formula (A) or formula (B) (where R1=H, C1 to C6 alkyl; R2=H, CH3; R3=C1 to C14 alkyl) or mixture thereof, b) 20 to 80 wt.% of polyvinylalcohol(PVA) and c) optionally 0 to 20 wt.% of other polymerizable compound (C). The method of producing the copolymer and the use of the copolymer as a coating agent, a binder and/or film-forming excipient in pharmaceutical dosage form are also provided.
Abstract:
PROBLEM TO BE SOLVED: To obtain the subject compound capable of manifesting good solubilizing actions on a hydrophobic drug without highly releasing histamine undesirable in parenteral application and useful as a solubilizing agent for medicines, cosmetic preparations and food preparations. SOLUTION: This hydroxylated carboxylic acid ester or amide represented by the formula [R1 is a 1-22C acyl or the like; R2 is a 1-16C alkyl or a 2-12C alkenyl; R3 is a 1-16C alkylene or the like; R4 is a 1-12C alkyl, a 2-12C alkenyl or the like; A is N(R5)-R6 (R5 is H, a 1-12C alkyl or the like; R6 is CH2-CH2); B is CH2-CH2-O, CH2-CH2-CH2-O or the like; (x) is 1-6; (y) is 0 or 1; (z) is 8-18], e.g. methyl 12-hydroxystearate polyethylene glycol (500) monoester is used as a solubilizing agent. The compound represented by the formula is capable of manifesting a good solubilizing power for an active ingredient of medicines and cosmetics without any adverse effects.
Abstract:
The invention relates to a rapidly dispersible, fine-grained, separation-resistant film coating agent for coating pharmaceutical dosage forms, consisting of a) 40 - 90 wt % of a polyvinyl alcohol-polyether graft copolymer (component A), b) 1 - 20 wt. % of a polyvinyl pyrrolidone or a vinyl pyrrolidone-vinyl acetate copolymer with a K-value of between 10 and 100 (component B), c) 10 - 60 wt. % of an organic or inorganic pigment with an average particle size that is less than 8 µm (component C), d) 0.5 - 15 wt. % of a surfactant with an HLB value that is greater than 10 (component D) and e) 0 - 30 wt % of additional conventional coating constituents (component E). In said agent, the particles of component C are embedded in a coherent polymer matrix and the quantity of components A to E totals 100 wt. %.
Abstract:
Disclosed is a method for producing gelatin-free soft capsule envelopes based on polyvinyl alcohol-polyether graft polymers as enveloping polymers. Said method is characterized in that an aqueous solution containing at least 45 percent by weight of a polymer component which comprises a polyvinyl alcohol-polyether graft polymer or a mixture of polyvinyl alcohol-polyether graft polymers and polyvinyl alcohol is heated, the percentage being in relation to the total weight of the solution, the solution is extruded at a minimum temperature of 70 °C, and the obtained film is solidified by cooling.
Abstract:
(Meth)acrylic acid copolymers used to increase the permeability of mucous membranes contain as comonomers (meth)acrylic acid esters and/or other radically polymerisable monomers, the molar ratio between (meth)acrylic acid and comonomer varying between 99:1 and 1:99.
Abstract:
The invention relates to a pharmaceutical formulation in the form of agglomerates containing a) 60 - 97 % by weight of sugar or sugar alcohols, b) 1 - 25 % by weight of cross-linked polyvinylpyrrolidone, c) 1 - 15 % by weight of water-insoluble, film-forming polymers, d) 0 - 15 % by weight of water-soluble polymers, and e) 0 - 15 % by weight of other pharmaceutically suitable adjuvants, the sum of components a) to e) adding up to 100 % by weight.
Abstract:
Carotinoids are used for preparing medicaments for treating inflammatory diseases that are not caused by exposure to light or by micro-organism infection.
Abstract:
The invention relates to a rapidly soluble film covering agent for covering solid substrates, comprising a) 10- 90 wt.- % of a polyvinylalcohol-polyether graft copolymer (component A), b) 5- 80 wt.- % of at least one additional component containing at least one functional group selected from the group containing hydroxy, amide and ester functions (component B), and c) 0- 70 wt.-% of additional standard coating components (components C).